Situated in the heart of Los Angeles is UCLA Jonsson Comprehensive Cancer Center (JCCC), which U.S. News & World Report rates as the “Best Medical Center” in the western United States as well as one of the nation’s best three hospitals.
As this University of California Los Angeles (UCLA) hospital is part of the University of California family, doctors and patients alike have direct access to a world-class medical center and research and teaching university, including state-of-the-art facilities, tools and equipment.
Through the Thoracic Oncology Program and the Division of Cardiac and Thoracic Surgery within UCLA’s World-renowned Lung Cancer Program, patients with mesothelioma, lung cancer and related thoracic malignancies are provided a team of specialists and support staff that collaborates to evaluate each patient’s case and develop a personalized treatment plan to deliver the best treatment possible.
Among the members who treat mesothelioma are:
In terms of treatment options for lung cancer and mesothelioma, patients have direct access to a wide array of services and programs, including surgical procedures, chemotherapy/targeted therapy, radiation therapy, clinical trials and the Thoracic Oncology Program tumor board and clinic.
As with any top-notch cancer treatment center, research is crucial, including laboratory-based findings, FDA-approved treatments and psychosocial and supportive care. The UCLA Lung Cancer Program is actually one of the nation’s seven institutions awarded the NCI’s Specialized Programs of Research Excellence (SPORE), a grant which promotes collaborative, interdisciplinary translational cancer research.
These researchers were responsible for the development of several successful targeted cancer therapies from science conducted at UCLA laboratories, including the lung cancer drug Tarceva (erlotinib). Other notable pharmaceutical developments have also been attributed to researchers across many disciplines when at UCLA as well, including drugs for leukemia and colorectal, lung and breast cancers.
Every year the institution’s 240-plus physicians and scientists handle more than 20,000 patient visits. This institution is hailed for its commitment to advancing the fields of cancer education and research, and for developing conventional and advanced cancer treatments.
Today JCCC is one of the nation’s largest “Comprehensive Cancer Centers.” This designation, which is presented by the National Cancer Institute (NCI), is offered to those institutions that maintain the highest standards of excellence in patient care, education, basic science, clinical research and cancer prevention.
Disclaimer: UCLA Jonsson Comprehensive Cancer Center has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More